Skip to main content
SpringerLink
Log in

Dual Mode of Action of Dihydropyridine Calcium Antagonists

A Role for Nitric Oxide

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Dihydropyridine calcium antagonists have been used for many years in the treatment of angina pectoris and hypertension. According to the common view, their mechanism of action is based on an inhibition of the smooth muscle L-type calcium current, thus decreasing intracellular calcium concentration and inducing smooth muscular relaxation. However, in recent years evidence has accumulated that besides the smooth muscle effects of these agents, their effect on the endothelium must also to be taken into account.

It was shown that dihydropyridines can induce the release of nitric oxide (NO) from the vascular endothelium of various vessels and in different species. This was first shown by Günther and colleagues by assaying the methaemoglobin formation in the presence of intact endothelium (in procine coronary arteries) with and without treatment with nitrendipine. These findings were later confirmed by direct measurement of NO or of nitrite production. In addition, in several preparations, including micro- and macrovasculature, the sensitivity of the vasorelaxing effect of the dihydropyridines to inhibitors of NO-synthase, such as L-NG-nitroarginine (LNNA) or L-N-nitro-arginine-methyl-ester ( L-NAME), has been shown. With these studies it became evident that the NO-releasing effect was not unique to nitrendipine but was a group phenomenon shared by the dihydropyridines and several nondihydropyridine calcium antagonists. In addition to their action on vascular endothelium, NO release by nifedipine has also been detected in platelets. There are also studies showing long term effects of calcium antagonists involving NO release.

Regarding the underlying mechanism of NO release, nitrendipine was shown, not to decrease but to increase intracellular Ca2+ in cultured endothelial cells. This increase was sensitive to both Ca2+-free extracellular superfusion and to gadolinium, a lanthanide known to inhibit shear-stress activated cation channels. This increase in intracellular calcium can activate endothelial NO-synthase, thus inducing the release of NO.

These findings on a dual mode of action, i.e. the direct relaxing effect by inhibition of the smooth muscle L-type calcium current and indirect relaxing effect by release of NO from vascular endothelium may help to understand the beneficial antihypertensive effects of the dihydropyridine calcium antagonists and the preferential effect of certain drugs in certain vascular regions (resistance versus conductive vessels). In addition, NO release from both vascular endothelium and platelets may contribute to the antiatherosclerotic and antithrombotic effects described for certain dihydropyridines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. Ann Rev Pharmacol Toxicol 1977; 17: 149–66

    Article  CAS  Google Scholar 

  2. Tsien RW, Lipscombe D, Madison DV, et al. Multiple types of neuronal calcium channels and their selective modulation. Trends Neurosci 1988; 11: 431–8

    Article  PubMed  CAS  Google Scholar 

  3. Schwartz A. Molecular and cellular aspects of calcium channel antagonism. Am J Cardiol 1992; 70: 6–8F

    Article  Google Scholar 

  4. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373–9

    Article  PubMed  CAS  Google Scholar 

  5. Ignarro L, Byrus RE, Buga GM, et al. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide. Circ Res 1987; 61: 866–79

    Article  PubMed  CAS  Google Scholar 

  6. Palmer RMJ, Ferridge AG, Moncada S. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524–6

    Article  PubMed  CAS  Google Scholar 

  7. Förstermann U, Mülsch A, Böhme E, et al. Stimulation of soluble guanylate cyclase by an acetylcholine-induced endothelium-derived relaxing factor from rabbit and canine arteries. Circ Res 1986; 58: 531–8

    Article  PubMed  Google Scholar 

  8. Kojda G, Werner G, Klaus W, et al. Reduced responses of nitrendipine in PGF2α precontracted porcine isolated arteries after pretreatment with methylene blue. Basic Res Cardiol 1990; 85: 461–6

    Article  PubMed  CAS  Google Scholar 

  9. Kojda G, Klaus W, Werner G, et al. The influence of endothelium on the action of PGF2α and some dihydropyridine type calcium antagonists in porcine basilar arteries. Basic Res Cardiol 1991; 86: 254–65

    Article  PubMed  CAS  Google Scholar 

  10. Ishii K, Chang B, Kerwin JF, et al. N-Nitro-L-Arginine: a potent inhibitor of endothelium-derived relaxing factor formation. Eur J Pharmacol 1990; 176: 219–23

    Article  PubMed  CAS  Google Scholar 

  11. Günther J, Dhein S, Rösen R, et al. Nitric oxide (EDRF) enhances the vasorelaxing effect of nitrendipine in various isolated arteries. Basic Res Cardiol 1992; 87: 452–60

    PubMed  Google Scholar 

  12. Feelisch M, Noack EA. Correlation between NO formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987; 139: 19–30

    Article  PubMed  CAS  Google Scholar 

  13. Dhein S, Zhao Y, Klaus W Microvascular actions of dihydropyridines in isolated mesenteric vascular beds and the involvement of nitric oxide [abstract]. Proceedings of the IBCs 3rd Symposium on Nitric Oxide; 1994 Mar 17–18; Philadelphia (PA): Abstract Book 1994; PB#22

  14. Dhein S, Zhao Y, Simsek S, et al. Actions of dihydropyridines in isolated mesenteric vascular beds. J Cardiovasc Pharmacol 1995; 26: 784–91

    Article  PubMed  CAS  Google Scholar 

  15. Berkels R, Bertsch A, Breitenbach T, et al. The calcium-antagonist nifedipine stimulates endothelial NO release in therapeutical concentrations. Pharmaceut Pharmacol Lett 1996; 6: 75–8

    CAS  Google Scholar 

  16. Rubanyi G, Schwarz A, Vanhoutte PM. Calcium transport mechanisms in endothelial cells regulating the synthesis and release of endothelium-derived relaxing factor. In: Vanhoutte PM, editor. Relaxing and contracting factors. Crescent Manor: Humana Press, 1988: 179–88

    Chapter  Google Scholar 

  17. Bossu JL, Elhamdani A, Feltz A, et al. Voltage gated Ca entry in isolated bovine capillary endothelial cells: evidence for a new type of Bay K 8644 sensitive channel. Pflügers Arch 1992; 402: 200–7

    Article  Google Scholar 

  18. Nilius B, Riemann D. Ion channels in human endothelial cells. Gen Physiol Biophys 1990; 9: 89–112

    PubMed  CAS  Google Scholar 

  19. Salameh A, Schomecker G, Breitkopf K, et al. The effect of the calcium-antagonist nitrendipine on intracellular calcium concentration in endothelial cells. Br J Pharmacol 1996; 118: 1899–904

    Article  PubMed  CAS  Google Scholar 

  20. Naruse K, Sokabe M. Involvement of stretch-activated ion channels in Ca++-mobilization to mechanical stretch in endothelial cells. Am J Physiol 1993; 264: C1037–44

    PubMed  CAS  Google Scholar 

  21. Hishikawa K, Nakai T, Marumo T, et al. Pressure enhances endothelin-1 release from cultured human endothelial cells. Hypertension 1995; 25: 449–52

    Article  PubMed  CAS  Google Scholar 

  22. Colden-Stanfield M, Schilling WP, Ritchie AK, et al. Bradykinin-induced increases in cytosolic calcium and ionic currents in cultured bovine aortic endothelial cells. Circ Res 1987; 61: 632–40

    Article  PubMed  CAS  Google Scholar 

  23. Akopov SE. Nitric oxide (EDRF) enhances the vasorelaxing effect of dihydropyridine calcium antagonists in isolated human middle cerebral arteries. Methods Find Exp Clin Pharmacol 1996; 18: 101–4

    PubMed  CAS  Google Scholar 

  24. Salameh A, Eisert A, Schomecker G, et al. Effects of nitrendipine, dotarizine and diltiazem on intracellular calcium in cultured bovine aortic endothelial cells [abstract]. Pharmacol Res 1995; 31 Suppl.: 227

    Article  Google Scholar 

  25. Tanguay M, Jasmin G, Baise G, et al. Coronary and cardiac sensitivity to the vasoselective benzothiazepine-like calcium antagonist, centiazem, in experimental heart failure. Cardiovasc Drugs Ther 1997; 11: 71–9

    Article  PubMed  CAS  Google Scholar 

  26. Mori T, Takeuchi T, Ohura M, et al. Pranidipine, a new dihydropyridine calcium channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta. Mol Cell Biochem 1998; 178: 335–43

    Article  PubMed  CAS  Google Scholar 

  27. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97: 576–80

    Article  PubMed  CAS  Google Scholar 

  28. Busse R, Lückhoff A, Winter I, et al. Fendiline and calmidazolium enhance the release of endothelium-derived relaxing factor and of prostacyclin from cultured endothelial cells. Naunyn Schmiedeberg’s Arch Pharmacol 1988; 337: 79–84

    Article  CAS  Google Scholar 

  29. Bennett MA, Hillier C, Thurston H. Endothelium-dependent relaxation in resistance arteries from spontaneously hypertensive rats: effect of long-term treatment with perindopril, quinapril, hydralazine or amlodipine. J Hypertens 1996; 14: 389–97

    Article  PubMed  CAS  Google Scholar 

  30. Takase H, Moreau P, Kung CF, et al. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency: effect of verapamil and trandolapril. Hypertension 1996; 27: 25–31

    Article  PubMed  CAS  Google Scholar 

  31. Dohi Y, Kojima M, Sato K. Benidipine improves endothelial function in renal resistance arteries of hypertensive rats. Hypertension 1996; 28: 58–63

    Article  PubMed  CAS  Google Scholar 

  32. Navarro-Cid J, Maeso R, Rodrigo E, et al. Renal and vascular consequences of the chronic nitric oxide synthase inhibition: effects of antihypertensive drugs. Am J Hypertens 1996; 9: 1077–83

    Article  PubMed  CAS  Google Scholar 

  33. Berkels R, Klaus W, Boiler M, et al. The calcium modulator nifedipine exerts antiaggregatory property via a nitric oxide mediated process. Thrombosis Haemostasis 1994; 72: 309–12

    CAS  Google Scholar 

  34. Kirschenbaum MA, Roh DD, Kamanna VS. Effect of nifedipine on renal microvascular cholesterol accumulation and prostacyclin biosynthesis in cholesterol-fed rabbits. Atherosclerosis 1991; 91: 241–6

    Article  PubMed  CAS  Google Scholar 

  35. Nicholson AC, Etingin OR, Pomerantz KB, et al. Dihydropyridine calcium antagonist modulates cholesterol metabolism and eicosanoid biosynthesis in vascular cells. J Cell Biochem 1992; 48: 393–400

    Article  PubMed  CAS  Google Scholar 

  36. Pirich C, Schmid P, Fitscha P, et al. Influence of calcium antagonists on platelet function and vascular prostacyclin production. Blood Press 1994; Suppl. 1: 75–80

    CAS  Google Scholar 

  37. Van Amsterdam FT, Roveri A, Maiorino M, et al. Lacidipine: a dihydropyridine calcium antagonist with antioxidant activity. Free Radic Biol Med 1992; 12: 183–7

    Article  PubMed  Google Scholar 

  38. Jacinto SM, Jandhyala BS. Evaluation of the effects of felodipine, verapamil and hydralazine on the survival rate of rats subjected to lethal effects of oxygen free radicals. Naunyn Schmiedeberg’s Arch Pharmacol 1992; 346: 457–61

    Article  CAS  Google Scholar 

  39. Reddy DS, Singh M, Chopra K. Comparative antioxidant effects of beta-adrenoceptor blockers, calcium antagonists and U74500A against iron-dependent lipid peroxidation in murine ventricular microsomal membranes. Methods Find Exp Clin Pharmacol 1996; 18: 559–67

    PubMed  CAS  Google Scholar 

  40. Tsuda K, Kuchii M, Nishio I, et al. Effects of calcium-antagonists on norepinephrine release from sympathetic nerve endings in rat mesenteric vasculature. Jpn Heart J 1986; 27: 395–402

    Article  PubMed  CAS  Google Scholar 

  41. Lichtlen PR, Hugenholz PG, Rafflenbeul W. Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 1990; 335: 1109–13

    Article  PubMed  CAS  Google Scholar 

  42. Fleckenstein-Grün G, Thimm F, Czirfuzs A, et al. Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations. J Cardiovasc Pharmacol 1994; 24 Suppl. 2: 75–84

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pharmacology, University Halle, Magdeburger Str. 4,06097, Halle (Saale), Germany

    Stefan Dhein

  2. Clinic III for Internal Medicine, Cologne, Germany

    Aida Salameh

  3. Institute of Pharmacology, University of Cologne, Cologne, Germany

    Reinhard Berkels & Wolfgang Klaus

Authors
  1. Stefan Dhein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aida Salameh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reinhard Berkels
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wolfgang Klaus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Dhein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dhein, S., Salameh, A., Berkels, R. et al. Dual Mode of Action of Dihydropyridine Calcium Antagonists. Drugs 58, 397–404 (1999). https://doi.org/10.2165/00003495-199958030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958030-00002

Keywords

Search

Navigation